Skip to main content

Table 2 Prevalence and objective response rate of patients with different statuses of  EGFR  gene

From: EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

Study  N  Prevalence (positive/total) Objective Response Rate (responder/total)
   Amplification High polysomy Other GCN+ GCN- Amplification High polysomy Other GCN+ GCN-
Campanella 201026 88 4/88   84/88 NR   NR
Frattini 200727 27 8/27 16/27 3/27   6/8 4/16 0/3
Gevorgyan 200728 40 8/40 19/40 12/40 0/8 0/19 5/13
Gonvalves 200829 29 0/29 2/29 10/29 17/29 NA 2/2 3/10 4/17
Italiano 200815 41 0/41 8/41 2/41 31/41 NA 2/8 8/33
Lievre 200631 30 3/30   27/30 3/3   8/27
Moroni 200514* 29 7/29 2/29 20/29 6/7 2/2 1/20
Perrone 200924 31 2/31 21/31 8/31 1/2 4/21 4/8
Personeni 200833 87 2/87 31/87 54/87 2/2 15/31 8/54
Sartore-Bianchi 200717 58 0/58   58/58 NA    6/58
Tol 201037 556 13/556 72/556 471/556 NR NR NR NR
  1. N, sample size; GCN+, increased gene copy number; GCN-, non-increased gene copy number; NR, not reported; NA, not applicable.
  2. * This study did not specify the criteria for “amplification” explicitly. We applied the most popular criterion (gene/CEP7 ≥ 2, see Table 1) to categorize the patients of this study.